All News
Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
December 17, 2019
The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical testing, necessitating TMZ dose reduction to ~15% of the single-agent maximum tolerated dose. We […]
Technology News Network: Team Develop Drugs To Fight Leukemia and Lymphoma
December 9, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2. “This is a new class of drugs called PROTACs that target […]
Briefings in Bioinformatics: Deep learning of pharmacogenomics resources: moving towards precision oncology
December 8, 2019
Yu-Chiao Chiu, Hung-I Harry Chen, Aparna Gorthi, Milad Mostavi, Siyuan Zheng, Yufei Huang, Yidong Chen Abstract The recent accumulation of cancer genomic data provides an opportunity to understand how a tumor’s genomic characteristics can affect its responses to drugs. This field, called pharmacogenomics, is a key area in the development of precision oncology. Deep learning (DL) methodology has emerged as a […]
BioNews Central: Leukemia, lymphoma squarely in sights of new class of drugs
December 6, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2.
EurekAlert: Leukemia, lymphoma squarely in sights of new class of drugs
December 6, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2.
SCITECH EUROPA: Preclinical Drug Development for Childhood Cancers
December 2, 2019
Pediatric Blood & Cancer: Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children’s Oncology Group Phase 1 Consortium study (ADVL1411)
November 14, 2019
Abstract Purpose We conducted a phase 1/2 trial of the poly(ADP‐ribose) polymerase 1/2 inhibitor talazoparib in combination with low‐dose temozolomide (TMZ) to determine the dose‐limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777). Methods Talazoparib […]
Aging Cell: mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging
November 6, 2019
Candice E. Van Skike, Ai‐Ling Lin, Raquel Roberts Burbank, Jonathan J. Halloran, Stephen F. Hernandez, James Cuvillier, Vanessa Y. Soto, Stacy A. Hussong, Jordan B. Jahrling, Martin A. Javors, Matthew J. Hart, Kathleen E. Fischer, Steven N. Austad, Veronica Galvan Abstract Cerebrovascular dysfunction and cognitive decline are highly prevalent in aging, but the mechanisms underlying these impairments are unclear. Cerebral blood flow decreases with aging and is […]